UTHR – United Therapeutics Corporation
UTHR — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
5.97
Margin Of Safety %
-5
Put/Call OI Ratio
0.71
EPS Next Q Diff
1.31
EPS Last/This Y
-2.82
EPS This/Next Y
4.31
Price
568.36
Target Price
677.33
Analyst Recom
1.47
Performance Q
19.79
Upside
66.8%
Beta
0.58
Ticker: UTHR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | UTHR | 573.14 | 0.73 | 0.03 | 32977 |
| 2026-04-24 | UTHR | 567.2 | 0.73 | 0.52 | 33021 |
| 2026-04-27 | UTHR | 567.24 | 0.73 | 0.90 | 33124 |
| 2026-04-28 | UTHR | 569.17 | 0.73 | 0.42 | 32972 |
| 2026-04-29 | UTHR | 570.51 | 0.73 | 0.55 | 32986 |
| 2026-04-30 | UTHR | 571.3 | 0.73 | 0.11 | 33009 |
| 2026-05-01 | UTHR | 570.06 | 0.73 | 1.94 | 33011 |
| 2026-05-04 | UTHR | 581.33 | 0.73 | 2.25 | 33035 |
| 2026-05-05 | UTHR | 572.45 | 0.74 | 0.50 | 33213 |
| 2026-05-06 | UTHR | 596.57 | 0.74 | 0.50 | 32313 |
| 2026-05-07 | UTHR | 569.48 | 0.72 | 1.38 | 42172 |
| 2026-05-08 | UTHR | 565.37 | 0.67 | 1.65 | 45458 |
| 2026-05-11 | UTHR | 569.69 | 0.67 | 0.74 | 45535 |
| 2026-05-12 | UTHR | 581.68 | 0.67 | 0.53 | 45611 |
| 2026-05-13 | UTHR | 579.67 | 0.66 | 0.44 | 48896 |
| 2026-05-14 | UTHR | 576.06 | 0.66 | 0.12 | 50010 |
| 2026-05-15 | UTHR | 568.61 | 0.65 | 0.09 | 50084 |
| 2026-05-18 | UTHR | 567.26 | 0.68 | 0.53 | 25117 |
| 2026-05-19 | UTHR | 567.07 | 0.68 | 0.64 | 25190 |
| 2026-05-20 | UTHR | 564.3 | 0.68 | 1.01 | 25224 |
| 2026-05-21 | UTHR | 566.11 | 0.70 | 5.42 | 25467 |
| 2026-05-22 | UTHR | 568.73 | 0.71 | 0.02 | 25608 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | UTHR | 573.06 | 3.6 | 418.3 | 28.39 |
| 2026-04-24 | UTHR | 567.21 | 3.6 | 393.2 | 28.39 |
| 2026-04-27 | UTHR | 567.16 | 3.6 | 387.6 | 28.39 |
| 2026-04-28 | UTHR | 569.16 | 3.6 | 401.5 | 28.39 |
| 2026-04-30 | UTHR | 571.51 | 6.2 | 411.6 | 28.57 |
| 2026-05-01 | UTHR | 570.15 | 6.2 | 328.3 | 28.57 |
| 2026-05-04 | UTHR | 581.51 | 6.2 | 375.5 | 28.57 |
| 2026-05-05 | UTHR | 572.60 | 6.2 | 338.4 | 28.57 |
| 2026-05-06 | UTHR | 596.31 | 6.2 | 475.8 | 28.57 |
| 2026-05-07 | UTHR | 569.60 | 6.2 | 326.0 | 28.57 |
| 2026-05-08 | UTHR | 564.76 | 6.2 | - | 28.57 |
| 2026-05-11 | UTHR | 569.82 | 6.2 | - | 28.57 |
| 2026-05-12 | UTHR | 581.66 | 8.7 | - | 27.42 |
| 2026-05-13 | UTHR | 579.49 | 8.7 | - | 27.42 |
| 2026-05-14 | UTHR | 575.85 | 8.7 | - | 27.42 |
| 2026-05-15 | UTHR | 568.65 | 8.7 | - | 27.42 |
| 2026-05-18 | UTHR | 566.87 | 8.7 | - | 27.42 |
| 2026-05-19 | UTHR | 566.99 | 8.7 | - | 27.42 |
| 2026-05-20 | UTHR | 564.14 | 8.7 | - | 27.42 |
| 2026-05-21 | UTHR | 565.81 | 8.7 | - | 27.42 |
| 2026-05-22 | UTHR | 568.36 | 7.9 | - | 27.31 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | UTHR | -45.85 | -0.94 | 6.71 |
| 2026-04-24 | UTHR | -45.68 | -0.94 | 6.71 |
| 2026-04-27 | UTHR | -45.71 | -1.00 | 6.39 |
| 2026-04-28 | UTHR | -45.71 | -1.00 | 6.39 |
| 2026-04-29 | UTHR | -45.83 | -1.00 | 6.39 |
| 2026-04-30 | UTHR | -45.86 | -1.00 | 6.39 |
| 2026-05-01 | UTHR | -45.50 | -1.00 | 6.39 |
| 2026-05-04 | UTHR | -45.47 | -1.20 | 6.39 |
| 2026-05-05 | UTHR | -45.47 | -1.20 | 6.39 |
| 2026-05-06 | UTHR | -45.44 | -1.20 | 6.39 |
| 2026-05-07 | UTHR | -45.47 | -1.20 | 6.39 |
| 2026-05-08 | UTHR | -45.66 | -1.20 | 6.39 |
| 2026-05-11 | UTHR | -46.82 | -0.14 | 6.60 |
| 2026-05-12 | UTHR | -47.00 | -0.14 | 5.98 |
| 2026-05-13 | UTHR | -46.39 | -0.14 | 5.98 |
| 2026-05-14 | UTHR | -46.21 | -0.14 | 5.98 |
| 2026-05-15 | UTHR | -46.40 | -0.14 | 5.98 |
| 2026-05-18 | UTHR | -46.77 | 1.46 | 5.98 |
| 2026-05-19 | UTHR | -45.96 | 1.46 | 5.98 |
| 2026-05-20 | UTHR | -46.34 | 1.46 | 5.98 |
| 2026-05-21 | UTHR | -46.37 | 1.46 | 5.97 |
| 2026-05-22 | UTHR | -47.72 | 1.46 | 5.97 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
5.82
Avg. EPS Est. Current Quarter
6.96
Avg. EPS Est. Next Quarter
7.13
Insider Transactions
-47.72
Institutional Transactions
1.46
Beta
0.58
Average Sales Estimate Current Quarter
810
Average Sales Estimate Next Quarter
824
Fair Value
539.62
Quality Score
100
Growth Score
96
Sentiment Score
74
Actual DrawDown %
6.7
Max Drawdown 5-Year %
-33
Target Price
677.33
P/E
20.98
Forward P/E
17.21
PEG
1.43
P/S
7.61
P/B
4.06
P/Free Cash Flow
23.73
EPS
27.09
Average EPS Est. Cur. Y
27.31
EPS Next Y. (Est.)
31.62
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
40.61
Relative Volume
0.48
Return on Equity vs Sector %
-5.2
Return on Equity vs Industry %
13.7
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-1.08
EBIT Estimation
◆
UTHR
Healthcare
$568.43
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
49.8
Range 1M
22.8%
Sup Dist
1.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
2%
EPS NY
16.2%
52W%
87.6%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+49.7% upside
Upside
+49.7%
Quality
100
MoS
-5%
United Therapeutics CorporationSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1400
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
UTHR
Latest News
—
Caricamento notizie per UTHR…
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading